Disitamab vedotin is an ADC consisting of a HER2-directed antibody and Monomethyl auristatin E (MMAE). Disitamab vedotin targets HER2 protein on tumors, recognizes and penetrates cancer cells with high precision, and releases the small molecule cytotoxic